Home > Insider Trading > Filing (0000950142-17-000629)

Filing Details

Accession Number:: 0000950142-17-000629
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-03-23 16:37:07
Reporting Period:: 2017-03-21

Filing Date:: 2017-03-23
Accepted Time:: 2017-03-23 16:37:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434868	Esperion Therapeutics Inc.	ESPR	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1120478	Md A Dov Goldstein	888 7Th Avenue 12Th Floor New York NY 10106		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-03-21	487,358	$43.48	1,149,767	No	4	S	Indirect	By Aisling Capital II, LP
Common Stock	Disposition	2017-03-22	312,642	$38.82	837,125	No	5	S	Indirect	By Aisling Capital II, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Aisling Capital II, LP
No	5	S	Indirect	By Aisling Capital II, LP

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $46.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 to $41.29, inclusive.